The researchers used Artificial Intelligence (AI)—in this case, computer image analysis of the initial MRI scans taken of brain cancer patients—and compared that image analysis with genomic research to analyze the cancer. The result: a new and more accurate way to not only determine the relative life expectancy of glioblastoma victims—but identify who could be candidates for experimental clinical drug trials.